| Lemtrada finally crosses the American finish line...

	Column 1	Column 2
0		Lemtrada finally crosses the American finish line (Subscription Only)
1	Source	EP Vantage
2	Company	Sanofi, Acorda Therapeutics, Biogen, Merck KGaA, Novartis, Teva Pharmaceutical Industries
3	Date	November 17, 2014
4		There were times when it might have looked easier for Sanofi to give up on Lemtrada, its seemingly jinxed multiple sclerosis treatment, which it had struggled to launch in a rapidly changing US market. But the French group’s perseverance has paid off and after more than two years of asking Lemtrada finally got a green light to US approval on Saturday. But with a strict label, onerous ongoing testing of patients and a designation for use in only third or fourth line, it will be an uphill battle for Sanofi to carve out sales in a space that has been all but conquered by less troubled oral treatments such as Biogen’s Tecfidera. Indeed, forecasts from EvaluatePharma show that Lemtrada will only just limp into the top 10 MS treatments by 2020